Electrical Muscle Stimulation for Acquired Weakness

(ICUAW Trial)

This trial aims to determine if the MyokinE100 System, a new device that sends electrical signals to thigh muscles, can help prevent muscle weakness in ICU patients. The trial will assess the device's safety and ease of use for critically ill individuals. Participants will receive either standard care alone or standard care with additional electrical muscle stimulation. Eligible participants must have been recently admitted to the ICU and be at risk for conditions like sepsis (a severe infection). As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance ICU care.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the MyokinE100 System, which uses electrical signals to stimulate muscles, is generally safe for patients. Most people do not experience serious side effects from this treatment. The MyokinE100 System aims to prevent muscle weakness in very ill patients, particularly those in the ICU, where muscle weakness is common.

Some patients have reported mild discomfort, such as tingling or muscle soreness, during the treatment. However, these effects are usually temporary and not serious. Additionally, electrical muscle stimulation is already used in other medical treatments, confirming its safety.

Most treatments for acquired muscle weakness in the ICU focus on standard physical therapy and supportive care. But the MyokinE100 System works differently by using electrical muscle stimulation (EMS) to directly activate muscle fibers. This method can potentially strengthen muscles faster and more effectively while patients are still in the ICU. Researchers are excited because EMS offers a non-invasive way to enhance muscle recovery, possibly reducing recovery time and improving outcomes for patients.

Research shows that electrical muscle stimulation can help reduce muscle weakness in very sick patients. In this trial, participants in the intervention group will receive electrical muscle stimulation using the MyokinE100 system. Studies have found that this system can slow muscle loss, especially in ICU patients. Early results suggest that patients tolerate the side effects, making it a promising option for those at risk of losing muscle strength. While more information is needed, directly stimulating muscles might help maintain strength during long ICU stays. This could potentially lead to better recovery and care for patients.¹²³⁵⁶